HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Criminal Charges For Repeat Spiked Supplement Marketer

This article was originally published in The Tan Sheet

Executive Summary

While Richard Deng faces criminal charges, other businesses marketing the same products seized from him avoid FDA enforcement by voluntarily recalling the products. Deng admitted he continued to sell adulterated products after his Beltsville, Md., store was searched and products were seized in 2011 and in 2013.

You may also be interested in...

More Criminal Cases Likely In Supplement, Food Safety, DoJ Official Says

The Obama administration supports pressing criminal charges in cases of contaminated or adulterated supplements or food products, and the Department of Justice is “working closely” with FDA’s food safety center, says DoJ Consumer Protection Branch official Jeffrey Steger.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts